Adverse events among COPD patients treated with long-acting anticholinergics and β2-agonists in an outpatient respiratory clinic

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in Canada. Most patients with COPD receive long-term treatment with long-acting anticholinergics (LAAC) and/or long-acting β2-agonists (LABA). Adverse events (AEs) are also likely during long-term treatment with these medications.

Source: Respiratory Medicine CME - February 17, 2016 Category: Respiratory Medicine Authors: Claudie Rodrigue, Marie-France Beauchesne, François Savaria, Amélie Forget, Catherine Lemière, Pierre Larivée, Lucie Blais, for the RESP Investigators Source Type: research